{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:51:29Z","timestamp":1767135089119,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd007477.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T00:00:00Z","timestamp":1401840000000}}],"reference-count":109,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007477.pub3","type":"journal-article","created":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T05:31:58Z","timestamp":1401859918000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Deferasirox for managing transfusional iron overload in people with sickle cell disease"],"prefix":"10.1002","volume":"2017","author":[{"given":"Joerg J","family":"Meerpohl","sequence":"first","affiliation":[{"name":"Medical Center - Univ. of Freiburg, Faculty of Medicine, Univ. of Freiburg; Cochrane Germany; Breisacher Stra\u00dfe 153 Freiburg Germany 79110"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa K","family":"Schell","sequence":"additional","affiliation":[{"name":"Institute for Quality and Efficiency in Health Care (IQWiG); Cologne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerta","family":"R\u00fccker","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Medical Center - University of Freiburg; Institute for Medical Biometry and Statistics; Stefan-Meier-Str. 26 Freiburg Germany 79104"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith","family":"Motschall","sequence":"additional","affiliation":[{"name":"Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg; Center for Medical Biometry and Medical Informatics; Stefan-Meier-Str. 26 Freiburg Germany 79104"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Fleeman","sequence":"additional","affiliation":[{"name":"University of Liverpool; Liverpool Reviews & Implementation Group; 2nd Floor, Sherrington Buildings Ashton Street Liverpool UK L69 3GE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte M","family":"Niemeyer","sequence":"additional","affiliation":[{"name":"University Medical Center Freiburg; Pediatric Hematology & Oncology, Center for Pediatrics & Adolescent Medicine; Mathildenstrasse 1 Freiburg Germany 79106"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Bassler","sequence":"additional","affiliation":[{"name":"University Hospital Zurich and University of Zurich; Department of Neonatology; Frauenklinikstrasse 10 Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,6,4]]},"reference":[{"key":"10.1002\/14651858.CD007477.pub3-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Cappellini MD Vichinsky E Ford JM Rabault B Porter J Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) <= 1000 ng\/mL in long-term studies Blood 2007 16B","DOI":"10.1182\/blood.V110.11.3795.3795"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Cappellini MD Vichinsky E Galanello R Piga A Williamson P Porter JB Long-term treatment with deferasirox (Exjade (R), ICL670), a once-daily oral iron chelator, is effective in patients with transfusion-dependent anemias Blood 2007 816A","DOI":"10.1182\/blood.V110.11.2777.2777"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Piga A Vichinsky E Forni GL Kilinc Y Maseruka H Kattamis A Long-term efficacy and safety with deferasirox (Exjade (R), ICL670), a once-daily oral iron chelator, in pediatric patients Blood 2007 815A","DOI":"10.1182\/blood.V110.11.2774.2774"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0011|cit4","unstructured":"Vichinsky E Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade\u00ae, ICL670) or deferoxamine (DFO) [abstract] 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA 2006 Abstract no: 174"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0012|cit5","unstructured":"Vichinsky E Results of a randomized, controlled phase two trials of deferasirox (Exjade\u00ae, ICL670) in sickle cell disease patients with chronic overload [abstract] 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 Apr 8-12; Memphis, USA. 2006 Abstract no: 175"},{"issue":"3","key":"10.1002\/14651858.CD007477.pub3-BIB0004|cit6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2141.2011.08720.x","article-title":"Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease","volume":"154","author":"Vichinsky","year":"2011","journal-title":"British Journal of Haematology"},{"issue":"11","key":"10.1002\/14651858.CD007477.pub3-BIB0005|cit7","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1182\/blood.V112.11.1420.1420","article-title":"Deferasirox (Exjade (R)), the Once-Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5-Year Follow-up","volume":"112","author":"Vichinsky","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0006|cit8","doi-asserted-by":"crossref","unstructured":"Vichinsky E Coates TD Thompson AA Mueller BU Lagrone D Heeney MM Long-term efficacy and safety of deferasirox (Exjade (R), ICL670), a once-daily oral iron chelator, in patients with sickle cell disease (SCD) Blood 2007 995A","DOI":"10.1182\/blood.V110.11.3395.3395"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0007|cit9","doi-asserted-by":"crossref","unstructured":"Vichinsky E Fischer R Fung E Onyekwere O Porter J Swerdlow P A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once-daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden Blood 2005 95A","DOI":"10.1182\/blood.V106.11.313.313"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0008|cit10","doi-asserted-by":"crossref","unstructured":"Vichinsky E Fischer R Pakbaz Z Onyekwere O Porter J Swerdlow P Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO) Blood 2005 656A 7A","DOI":"10.1182\/blood.V106.11.2334.2334"},{"issue":"3","key":"10.1002\/14651858.CD007477.pub3-BIB0009|cit11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2141.2006.06455.x","article-title":"A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease","volume":"136","author":"Vichinsky","year":"2007","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1002\/14651858.CD007477.pub3-BIB0010|cit12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000125550","article-title":"Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial","volume":"119","author":"Vichinsky","year":"2008","journal-title":"Acta Haematologica"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0013|cit13","unstructured":"Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients http:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00110617"},{"issue":"21","key":"10.1002\/14651858.CD007477.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.V118.21.1082.1082","article-title":"A randomized phase II study evaluating the efficacy and safety of deferasirox versus deferoxamine in patients with sickle cell disease (SCD): 2-year results including pharmacokinetics (PK) and safety of deferasirox with concomitant hydroxyurea therapy [abstract]","volume":"118","author":"Vichinsky","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD007477.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/ajh.23569","article-title":"Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea","volume":"88","author":"Vichinsky","year":"2013","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"Aygun B Mortier NA Kesler K Schultz WH Alvarez OA Rogers ZR Therapeutic Phlebotomy in Children with Sickle Cell Anemia, Stroke, and Iron Overload: The SWiTCH Experience Blood 2011 481 2","DOI":"10.1182\/blood.V118.21.1044.1044"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Kwiatkowski JL Cohen AR Garro J Alvarez O Nagasubramanian R Sarnaik S Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention American Journal of Hematology 2012 221 3","DOI":"10.1002\/ajh.22228"},{"issue":"17","key":"10.1002\/14651858.CD007477.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1182\/blood-2011-11-392340","article-title":"Stroke with transfusions changing to hydroxyurea (SWITCH)","volume":"119","author":"Ware","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD007477.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM199807023390102","article-title":"Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography","volume":"339","author":"Adams","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"26","key":"10.1002\/14651858.CD007477.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1056\/NEJMoa050460","article-title":"Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease","volume":"353","author":"Adams","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1749-6632.1998.tb10482.x","article-title":"Global epidemiology of hemoglobin disorders","volume":"850","author":"Angastiniotis","year":"1998","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"4","key":"10.1002\/14651858.CD007477.pub3-BIB0022|cit22","first-page":"477","article-title":"Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials","volume":"170","author":"Bhandari","year":"2004","journal-title":"CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne"},{"issue":"10","key":"10.1002\/14651858.CD007477.pub3-BIB0023|cit23","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"Borgna-Pignatti","year":"2004","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0024|cit24","doi-asserted-by":"crossref","unstructured":"Brittenham GM Farrell DE Harris JW Feldman ES Danish EH Muir WA Magnetic-susceptibility measurement of human iron stores New England Journal of Medicine 1982 1671 5","DOI":"10.1056\/NEJM198212303072703"},{"issue":"9","key":"10.1002\/14651858.CD007477.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM199409013310902","article-title":"Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major","volume":"331","author":"Brittenham","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007477.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMct1004810","article-title":"Iron-chelating therapy for transfusional iron overload","volume":"364","author":"Brittenham","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD007477.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1053\/j.seminhematol.2005.01.001","article-title":"Overcoming the challenge of patient compliance with iron chelation therapy","volume":"42","author":"Cappellini","year":"2005","journal-title":"Seminars in Hematology"},{"issue":"9","key":"10.1002\/14651858.CD007477.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD007477.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.clinthera.2007.05.007","article-title":"Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia","volume":"29","author":"Cappellini","year":"2007","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Cappellini MD Vichinsky E Ford JM Rabault B Porter J Evaluation of deferasirox (Exjade (R), ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) <= 1000 ng\/mL in long-term studies Blood 2007 16B","DOI":"10.1182\/blood.V110.11.3795.3795"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0031|cit31","doi-asserted-by":"crossref","unstructured":"Cappellini MD Vichinsky E Galanello R Piga A Williamson P Porter JB Long-term treatment with deferasirox (Exjade (R), ICL670), a once-daily oral iron chelator, is effective in patients with transfusion-dependent anemias Blood 2007 816A","DOI":"10.1182\/blood.V110.11.2777.2777"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0268-960X(08)70007-9","article-title":"Long-term efficacy and safety of deferasirox","volume":"22 Suppl 2","author":"Cappellini","year":"2008","journal-title":"Blood Reviews"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev.med.60.041807.123243","article-title":"Oral iron chelators","volume":"60","author":"Cappellini","year":"2009","journal-title":"Annual Review of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007477.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"557-66","DOI":"10.3324\/haematol.2009.014696","article-title":"Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias","volume":"95","author":"Cappellini","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"10.1002\/14651858.CD007477.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1046\/j.1365-2141.2002.03554.x","article-title":"The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients","volume":"118","author":"Ceci","year":"2002","journal-title":"British Journal of Haematology"},{"issue":"15","key":"10.1002\/14651858.CD007477.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/sim.1205","article-title":"Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes","volume":"21","author":"Curtin","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"15","key":"10.1002\/14651858.CD007477.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1002\/sim.1206","article-title":"Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes","volume":"21","author":"Curtin","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"15","key":"10.1002\/14651858.CD007477.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1002\/sim.1207","article-title":"Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over","volume":"21","author":"Curtin","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007477.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1515\/jpem-2006-190404","article-title":"Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia","volume":"19","author":"Sanctis","year":"2006","journal-title":"Journal of pediatric endocrinology & metabolism : JPEM"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0040|cit40","article-title":"Chapter 9: Analysing data and undertaking meta-analyses","volume-title":"In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org","author":"Deeks","year":"2008"},{"issue":"4","key":"10.1002\/14651858.CD007477.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ajh.21049","article-title":"Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States","volume":"83","author":"Delea","year":"2008","journal-title":"American Journal of Hematology"},{"issue":"11","key":"10.1002\/14651858.CD007477.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1007\/s00467-012-2170-4","article-title":"Deferasirox-induced renal impairment in children: an increasing concern for pediatricians","volume":"27","author":"Dubourg","year":"2012","journal-title":"Pediatric Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD007477.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0044|cit44","unstructured":"European Medicines Agency London UK Exjade: European Public Assessment Report: Summary of Product Characteristics www.emea.europa.eu\/humandocs\/Humans\/EPAR\/exjade\/exjade.htm"},{"issue":"4","key":"10.1002\/14651858.CD007477.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2141.2006.06203.x","article-title":"Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major","volume":"134","author":"Farmaki","year":"2006","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0046|cit46","unstructured":"Food Drug Administration (FDA) USA Exjade www.fda.gov\/cder\/foi\/label\/2007\/021882s002lbl\/pdf"},{"issue":"8","key":"10.1002\/14651858.CD007477.pub3-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004450.pub3","article-title":"Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia","author":"Fisher","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD007477.pub3-BIB0048|cit48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004839.pub3","article-title":"Oral deferiprone for iron chelation in people with thalassaemia","author":"Fisher","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD007477.pub3-BIB0049|cit49","first-page":"565","article-title":"Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions","volume":"144","author":"Freedman","year":"1990","journal-title":"American Journal of Diseases of Children"},{"issue":"1","key":"10.1002\/14651858.CD007477.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000203853","article-title":"Results of long-term iron-chelating therapy","volume":"95","author":"Gabutti","year":"1996","journal-title":"Acta Haematologica"},{"issue":"9","key":"10.1002\/14651858.CD007477.pub3-BIB0051|cit51","first-page":"1241","article-title":"A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia","volume":"91","author":"Galanello","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"10.1002\/14651858.CD007477.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1517\/17425255.2012.640674","article-title":"Deferasirox: pharmacokinetics and clinical experience","volume":"8","author":"Galanello","year":"2012","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"issue":"13","key":"10.1002\/14651858.CD007477.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1001\/jama.1983.03330370053031","article-title":"If nothing goes wrong, is everything all right? Interpreting zero numerators","volume":"249","author":"Hanley","year":"1983","journal-title":"JAMA : the journal of the American Medical Association"},{"issue":"11","key":"10.1002\/14651858.CD007477.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD007477.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0056|cit56","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org","author":"Higgins","year":"2008"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0057|cit57","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"issue":"8660","key":"10.1002\/14651858.CD007477.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(89)90641-7","article-title":"Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial","volume":"2","author":"Hoffbrand","year":"1989","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD007477.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2002-06-1867","article-title":"Role of deferiprone in chelation therapy for transfusional iron overload","volume":"102","author":"Hoffbrand","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD007477.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.tmrv.2006.11.003","article-title":"Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines","volume":"21","author":"Josephson","year":"2007","journal-title":"Transfusion Medicine Reviews"},{"issue":"12","key":"10.1002\/14651858.CD007477.pub3-BIB0061|cit61","first-page":"1423","article-title":"Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion","volume":"88","author":"Kattamis","year":"2003","journal-title":"Haematologica"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD007477.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1111\/j.1524-4733.2009.00633.x","article-title":"A time-cost augmented economic evaluation of oral deferasirox versus infusional deferoxamine [corrected] for patients with iron overload in South Korea","volume":"12","author":"Kim","year":"2009","journal-title":"Value in Health"},{"issue":"1-2","key":"10.1002\/14651858.CD007477.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/03630260701727085","article-title":"Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine\/deferiprone combination. Identification of effective chelation therapy protocols","volume":"32","author":"Kolnagou","year":"2008","journal-title":"Hemoglobin"},{"issue":"6612","key":"10.1002\/14651858.CD007477.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1136\/bmj.295.6612.1509","article-title":"Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one","volume":"295","author":"Kontoghiorghes","year":"1987","journal-title":"BMJ (Clinical Research Edition)"},{"issue":"8545","key":"10.1002\/14651858.CD007477.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0140-6736(87)90545-9","article-title":"1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload","volume":"1","author":"Kontoghiorghes","year":"1987","journal-title":"Lancet"},{"issue":"9873","key":"10.1002\/14651858.CD007477.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1183-4","DOI":"10.1016\/S0140-6736(13)60799-0","article-title":"Turning a blind eye to deferasirox's toxicity?","volume":"381","author":"Kontoghiorghes","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD007477.pub3-BIB0067|cit67","first-page":"371","article-title":"The effects of subcutaneous deferoxamine administration on renal function in thalassemia major","volume":"54","author":"Koren","year":"1991","journal-title":"International Journal of Hematology"},{"issue":"10","key":"10.1002\/14651858.CD007477.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1016\/j.clinthera.2007.10.015","article-title":"Deferasirox for transfusion-related iron overload: a clinical review","volume":"29","author":"Lindsey","year":"2007","journal-title":"Clinical therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD007477.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2011.08769.x","article-title":"Chelation treatment in sickle-cell anaemia: much ado about nothing?","volume":"154","author":"Lucania","year":"2011","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1002\/14651858.CD007477.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/bcmd.2002.0510","article-title":"Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial","volume":"28","author":"Maggio","year":"2002","journal-title":"Blood Cells, Molecules & Diseases"},{"issue":"1","key":"10.1002\/14651858.CD007477.pub3-BIB0071|cit71","first-page":"iii-iv, ix-xi,","article-title":"Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation","volume":"13","author":"McLeod","year":"2009","journal-title":"Health Technology Assessment (Winchester, England)"},{"issue":"2","key":"10.1002\/14651858.CD007477.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1056\/NEJM200001133420203","article-title":"Prediction of adverse outcomes in children with sickle cell disease","volume":"342","author":"Miller","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"9220","key":"10.1002\/14651858.CD007477.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(00)02357-6","article-title":"Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register","volume":"355","author":"Modell","year":"2000","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD007477.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"Global epidemiology of haemoglobin disorders and derived service indicators","volume":"86","author":"Modell","year":"2008","journal-title":"Bulletin of the World Health Organization"},{"issue":"9369","key":"10.1002\/14651858.CD007477.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(03)13309-0","article-title":"Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"361","author":"Nisbet-Brown","year":"2003","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD007477.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199409013310903","article-title":"Survival in medically treated patients with homozygous beta-thalassemia","volume":"331","author":"Olivieri","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007477.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V89.3.739","article-title":"Iron-chelating therapy and the treatment of thalassemia","volume":"89","author":"Olivieri","year":"1997","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD007477.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199808133390701","article-title":"Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major","volume":"339","author":"Olivieri","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD007477.pub3-BIB0079|cit79","first-page":"1309","article-title":"Combined therapy with deferiprone and desferrioxamine in thalassemia major","volume":"90","author":"Origa","year":"2005","journal-title":"Haematologica"},{"issue":"24","key":"10.1002\/14651858.CD007477.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"1-2","key":"10.1002\/14651858.CD007477.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/03630260701680078","article-title":"Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience","volume":"32","author":"Peng","year":"2008","journal-title":"Hemoglobin"},{"issue":"7","key":"10.1002\/14651858.CD007477.pub3-BIB0082|cit82","first-page":"873","article-title":"Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload","volume":"91","author":"Piga","year":"2006","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0083|cit83","doi-asserted-by":"crossref","unstructured":"Piga A Vichinsky E Forni GL Kilinc Y Maseruka H Kattamis A Long-term efficacy and safety with deferasirox (Exjade (R), ICL670), a once-daily oral iron chelator, in pediatric patients Blood 2007 815A","DOI":"10.1182\/blood.V110.11.2774.2774"},{"issue":"1","key":"10.1002\/14651858.CD007477.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199107043250103","article-title":"Pain in sickle cell disease. Rates and risk factors","volume":"325","author":"Platt","year":"1991","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007477.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.md.0000189089.45003.52","article-title":"Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients","volume":"84","author":"Powars","year":"2005","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1002\/14651858.CD007477.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"616-20","DOI":"10.1002\/pbc.21929","article-title":"Oral iron chelation and the treatment of iron overload in a pediatric hematology center","volume":"52","author":"Raphael","year":"2009","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0087|cit87","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) [Computer program] 2012"},{"issue":"4","key":"10.1002\/14651858.CD007477.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1399-0004.2005.00503.x","article-title":"The hemoglobinopathies and malaria","volume":"68","author":"Richer","year":"2005","journal-title":"Clinical Genetics"},{"issue":"14","key":"10.1002\/14651858.CD007477.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","article-title":"A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance","volume":"115","author":"Tanner","year":"2007","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD007477.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1345\/aph.1G566","article-title":"Deferasirox--an oral agent for chronic iron overload","volume":"40","author":"VanOrden","year":"2006","journal-title":"Annals of Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD007477.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/ajh.20402","article-title":"Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia","volume":"80","author":"Vichinsky","year":"2005","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0092|cit92","doi-asserted-by":"crossref","unstructured":"Vichinsky E Fischer R Fung E Onyekwere O Porter J Swerdlow P A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demonstrates that the once-daily oral iron chelator deferasirox (Exjade((R)) ICL670) is well tolerated and reduces iron burden Blood 2005 95A","DOI":"10.1182\/blood.V106.11.313.313"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0093|cit93","doi-asserted-by":"crossref","unstructured":"Vichinsky E Fischer R Pakbaz Z Onyekwere O Porter J Swerdlow P Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade((R)), ICL670) and deferoxamine (DFO) Blood 2005 656A 7A","DOI":"10.1182\/blood.V106.11.2334.2334"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0094|cit94","unstructured":"Vichinsky E Results of a randomized, controlled phase two trials of deferasirox (Exjade\u00ae, ICL670) in sickle cell disease patients with chronic overload [abstract] 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 April 8-12; Memphis, USA. 2006 Abstract no: 175"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0095|cit95","unstructured":"Vichinsky E Patient reported outcomes with chelation therapy in patients with sickle cell disease (SCD) on either deferasirox (Exjade\u00ae, ICL670) or deferoxamine (DFO) [abstract] 29th Annual Meeting of The National Sickle Cell Disease Program; 2006 April 8-12; Memphis, USA 2006 Abstract no: 174"},{"issue":"3","key":"10.1002\/14651858.CD007477.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2141.2006.06455.x","article-title":"A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease","volume":"136","author":"Vichinsky","year":"2007","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Vichinsky E Coates TD Thompson AA Mueller BU Lagrone D Heeney MM Long-term efficacy and safety of deferasirox (Exjade (R), ICL670), a once-daily oral iron chelator, in patients with sickle cell disease (SCD) Blood 2007 995A","DOI":"10.1182\/blood.V110.11.3395.3395"},{"issue":"3","key":"10.1002\/14651858.CD007477.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000125550","article-title":"Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial","volume":"119","author":"Vichinsky","year":"2008","journal-title":"Acta Haematologica"},{"issue":"11","key":"10.1002\/14651858.CD007477.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1182\/blood.V112.11.1420.1420","article-title":"Deferasirox (Exjade (R)), the Once-Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5-Year Follow-up","volume":"112","author":"Vichinsky","year":"2008","journal-title":"Blood"},{"issue":"2-3","key":"10.1002\/14651858.CD007477.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000243802","article-title":"Iron metabolism and iron chelation in sickle cell disease","volume":"122","author":"Walter","year":"2009","journal-title":"Acta Haematologica"},{"issue":"5","key":"10.1002\/14651858.CD007477.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood-2002-01-0306","article-title":"Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia","volume":"100","author":"Wanless","year":"2002","journal-title":"Blood"},{"key":"10.1002\/14651858.CD007477.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.1998.tb10456.x","article-title":"Thalassemia in the next millennium. Keynote address","volume":"850","author":"Weatherall","year":"1998","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"22","key":"10.1002\/14651858.CD007477.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1002\/sim.1303","article-title":"Aggregate data meta-analysis with time-to-event outcomes","volume":"21","author":"Williamson","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007477.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1055\/s-0038-1633900","article-title":"Some problems with the investigation of noninferiority in meta-analysis","volume":"43","author":"Witte","year":"2004","journal-title":"Methods of Information in Medicine"},{"issue":"25","key":"10.1002\/14651858.CD007477.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM198506203122503","article-title":"Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major","volume":"312","author":"Wolfe","year":"1985","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007477.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/03630260600642534","article-title":"Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients","volume":"30","author":"Wu","year":"2006","journal-title":"Hemoglobin"},{"issue":"3","key":"10.1002\/14651858.CD007477.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"587-90","DOI":"10.1053\/j.ajkd.2008.03.034","article-title":"Hypocalcemia in a dialysis patient treated with deferasirox for iron overload","volume":"52","author":"Yusuf","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"8653","key":"10.1002\/14651858.CD007477.pub3-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(89)90264-X","article-title":"Survival and causes of death in thalassaemia major","volume":"2","author":"Zurlo","year":"1989","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD007477.pub3-BIB0109|cit109","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007477.pub2","article-title":"Deferasirox for managing transfusional iron overload in people with sickle cell disease","author":"Meerpohl","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD007477.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T05:00:10Z","timestamp":1716786010000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007477.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,6,4]]},"references-count":109,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007477.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,4]]}}}